Terms: = Kidney tumors AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
6 results:
1. Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma.
Sun Z; Wang J; Fan Z; Yang Y; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Liu Y; Yang Q; Ma B
J Gene Med; 2024 Jan; 26(1):e3608. PubMed ID: 37897262
[TBL] [Abstract] [Full Text] [Related]
2. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.
Procopio G; Apollonio G; Cognetti F; Miceli R; Milella M; Mosca A; Chiuri VE; Bearz A; Morelli F; Ortega C; Atzori F; Donini M; Ratta R; Raimondi A; Claps M; Martinetti A; Capitanio U; de Braud FG; Cappelletti V; Verzoni E
Eur Urol Oncol; 2019 Nov; 2(6):699-707. PubMed ID: 31542243
[TBL] [Abstract] [Full Text] [Related]
3. PTEN in kidney cancer: A review and meta-analysis.
Que WC; Qiu HQ; Cheng Y; Liu MB; Wu CY
Clin Chim Acta; 2018 May; 480():92-98. PubMed ID: 29408173
[TBL] [Abstract] [Full Text] [Related]
4. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Jonasch E; Corn P; Pagliaro LC; Warneke CL; Johnson MM; Tamboli P; Ng C; Aparicio A; Ashe RG; Wright JJ; Tannir NM
Cancer; 2010 Jan; 116(1):57-65. PubMed ID: 19862815
[TBL] [Abstract] [Full Text] [Related]
5. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
Okuno T; Tamura T; Yamamori M; Chayahara N; Yamada T; Miki I; Okamura N; Kadowaki Y; Shirasaka D; Aoyama N; Nakamura T; Okumura K; Azuma T; Kasuga M; Sakaeda T
Am J Clin Oncol; 2007 Jun; 30(3):252-7. PubMed ID: 17551301
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
